|Articles|April 11, 2017

GMP Laboratory Testing Services

Eurofins BioPharma Product Testing is the largest network of harmonized bio/pharmaceutical GMP product testing laboratories worldwide providing comprehensive laboratory services for the world’s largest pharmaceutical, biopharmaceutical and medical device companies.

 

Our service offerings are fully comprehensive and include testing of drug substance, final product, intermediates, and starting materials for both small and large molecule drug products.

 

With a global capacity of more than 65,000 square meters and facilities located in Australia, Belgium, Canada, Denmark, France, Germany, Ireland, Italy, Netherlands, Spain, Sweden, UK and the US, our network of GMP laboratories operates under the same strict quality procedures, LIMS and centralized billing system across 25 locations worldwide.

 

We give our clients the flexibility to choose from three unique service models to meet specific project needs, including the award-winning Professional Scientific Services® (PSS) and we also provide secure 24-hour data access via our online data portal, LabAccess.com SM.

 

Contact Details

Company name: Eurofins BioPharma Product Testing
Website: Eurofins.com/Biopharma
E-mail: pharma@eurofins.com

Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.